|
**Overview**: **Main Test Pack 2 Profile****Introduction**: The Main Test Pack 2 Profile is a diagnostic tool designed for comprehensive health screening using serum and whole blood samples. Associated with conditions like diabetes and anemia, these disorders present with fatigue, weight changes, and severe complications if untreated, particularly in individuals with general health concerns. Per the 2023 Biochemistry and Hematology guidelines, the test employs biochemistry and hematology with spectrophotometry and automated cell counter technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for routine check-ups in clinical settings. This diagnostic falls under routine check-up and targets individuals seeking comprehensive health evaluation, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.**Other Names**: Main Test 2 Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry and hematology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1980s by clinical labs, this test advanced comprehensive health screening.**Purpose**: The test screens for 21 parameters including hemoglobin to guide health assessment, assess metabolic and hematological status, and inform treatment and prevention strategies.**Test Parameters**: 1. Hemoglobin, 2. RBC Count, 3. WBC Count, 4. Platelet Count, 5. ESR, 6. Fasting Glucose, 7. HbA1c, 8. Total Cholesterol, 9. HDL, 10. LDL, 11. Triglycerides, 12. Total Bilirubin, 13. AST, 14. ALT, 15. ALP, 16. Creatinine, 17. Urea, 18. Sodium, 19. Potassium, 20. Calcium, 21. TSH.**Pretest Condition**: Fasting 10-12 hours required; patients should report fatigue, weight changes, or recent health symptoms.**Specimen**: 3 mL serum in 1 SST, 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours (Serum), 48 hours (Blood) with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days (Serum, Blood) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months (Serum) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fatigue, weight changes, prior health reactions, or family history of chronic diseases, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated conditions including organ damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry and automated cell counter and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible health issues, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in internal medicine should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Imaging or specific panels for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in acute illness, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry and Hematology Guidelines 2023, Journal of Clinical Medicine 2024, Chemistry 2025. |
